ERICA HAN: Open Payments
NPI 1073806022 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,303 in 61 payments from 14 companies in 2025. Trend: 2023 $3,502 · 2024 $696 · 2025 $1,303
Food & beverage: $1,269Education: $34
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 11 | $346 |
| Regeneron Healthcare Solutions, Inc. | 9 | $200 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $173 |
| GlaxoSmithKline, LLC. | 10 | $169 |
| ARS Pharmaceuticals Operations, Inc. | 13 | $142 |
| Optinose US, Inc. | 2 | $50 |
| Amgen Inc. | 2 | $48 |
| Novartis Pharmaceuticals Corporation | 2 | $47 |
| GENZYME CORPORATION | 1 | $32 |
| Galderma Laboratories, L.P. | 1 | $26 |
Products named: DUPIXENT, TEZSPIRE, NUCALA, CUVITRU, NEFFY, FASENRA, Xhance, AIRSUPRA.
Industry payments across TX — which companies pay providers there.
